Reach Us +44-1202-068036
Thymosin Apha 1and#8211;A Peptide Immune Modulator with a Broad Range of Clinical Applications | OMICS International | Abstract
ISSN: 2161-1459

Journal of Clinical & Experimental Pharmacology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications

Cynthia W. Tuthill* and Robert S. King

SciClone Pharmaceuticals Inc., 950 Tower Lane, Suite 900, Foster City, California, USA

*Corresponding Author:
Cynthia W. Tuthill, PhD
SciClone Pharmaceuticals Inc.
950 Tower Lane, Suite 900
Foster City, CA 94404, USA
E-mail: [email protected]

Received date: June 27, 2013; Accepted date: September 24, 2013; Published date: October 01, 2013

Citation: Tuthill CW, King RS (2013) Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications. Clin Exp Pharmacol 3:133. doi: 10.4172/2161-1459.1000133

Copyright: © 2013 Tuthill CW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Thymosin alpha 1 (thymalfasin, Ta1), the active ingredient in ZADAXIN®, is a peptidic biological response modifier which activates various cells of the immune system. Ta1 is therefore expected to have clinical benefits in disorders where immune responses are impaired or ineffective, such as acute and chronic infections, cancers, and vaccine non-responsiveness, all of which are hallmarks of an impaired or inadequate immune response. Importantly, Ta1 acts without overstimulation of cytokine production and is generally well tolerated; it has an excellent safety profile and does not appear to induce the side effects and toxicities commonly associated with agents in this class such as interferonalpha and interleukin-2.

Ta1 has been shown to act through Toll-like receptors, linking to intracellular cell-signaling pathways and leading to stimulation of the immune system, including T helper cells, cytotoxic T cells, and natural killer cells.

Clinical studies with Ta1 have been conducted and shown evidence of benefit in subjects with acute or chronic viral or bacterial infections, including subjects with severe sepsis, infections after bone marrow transplant, chronic hepatitis B or C, or acquired immune deficiency syndrome. Ta1 has also shown promise in clinical evaluation as an adjunctive treatment in subjects suffering from various types of cancer, including hepatocellular carcinoma, non-small-cell lung cancer, melanoma, renal, breast and gastric cancers; and in subjects receiving vaccines (geriatric subjects receiving influenza vaccine and subjects with renal failure receiving influenza or hepatitis vaccine).


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry


[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version